Skip to main content
Top
Published in:

Open Access 01-12-2024 | Methodology

Analytic performance of ScreenFire HPV RS assay Zebra BioDome format and its potential for large-scale population HPV screening

Authors: Jun Wang, Godwin Imade, Alani S. Akanmu, Jonah Musa, Rose Anorlu, Yinan Zheng, Olga Garcia-Bedoya, Gloria I. Sanchez, Jerome Belinson, Kyeezu Kim, Mamoudou Maiga, Demirkan B. Gursel, Atiene S. Sagay, Folasade T. Ogunsola, Robert L. Murphy, Lifang Hou

Published in: Infectious Agents and Cancer | Issue 1/2024

Login to get access

Abstract

Background

Easy-to-use, rapid, scalable, high-throughput, and cost-effective HPV tests are urgently needed for low-resource settings. Atila Biosystems’ high-throughput, cost-effective, and clinically validated ScreenFire HPV Risk Stratification (RS) assay identifies 13 high risk HPV (hrHPV) in 4 groups based on their oncogenic risk (i.e., HPV16, HPV18/45, HPV31/33/35/52/58, and HPV51/59/39/56/68). The current standard format is subject to laboratory contamination, which is common for any molecular PCR test. To overcome this drawback, Atila has recently upgraded it into an innovative, contamination-free Zebra BioDome format. The contamination-free feature makes this novel assay format more suitable for large-scale community- and population-based cervical screening. This study evaluated the analytical performance of the Zebra BioDome format.

Methods

We conducted a study to test the analytical performance of Zebra Biodome format in comparison to the results of using the ScreenFire HPV RS assay standard format on Biorad CFX-96 real-time PCR instrument. We used overall agreement rate and unweighted kappa value to compare the performance.

Results

The overall agreement for detection of hrHPV was 96.0% with unweighted kappa value 0.94 (95% confidence interval: 0.90–0.98). The agreement rates between hrHPV genotype 16 and risk stratification genotype group (HPV18/45, HPV31/33/35/52/58, and HPV51/59/39/56/68) were all > 97.5%.

Conclusion

The innovative ScreenFire HPV RS assay Zebra BioDome format produced highly concordant results with the standard format. The shared features by the two assay formats, such as easy-to-use, high throughput, cost-appropriate, and no requirements for DNA extraction. The unique contamination-prevention feature along with no requirement of preparation of reagents make the Zebra BioDome format more suitable for large-scale HPV screening to reduce global cervical cancer burden.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.CrossRefPubMed
2.
go back to reference Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–203.CrossRefPubMed Arbyn M, Weiderpass E, Bruni L, de Sanjosé S, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health. 2020;8:e191–203.CrossRefPubMed
3.
go back to reference Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4:e609–16.CrossRefPubMed Plummer M, de Martel C, Vignat J, Ferlay J, Bray F, Franceschi S. Global burden of cancers attributable to infections in 2012: a synthetic analysis. Lancet Global Health. 2016;4:e609–16.CrossRefPubMed
4.
go back to reference Small W Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–12.CrossRefPubMed Small W Jr., Bacon MA, Bajaj A, Chuang LT, Fisher BJ, Harkenrider MM, Jhingran A, Kitchener HC, Mileshkin LR, Viswanathan AN, Gaffney DK. Cervical cancer: a global health crisis. Cancer. 2017;123:2404–12.CrossRefPubMed
5.
go back to reference Huber J, Mueller A, Sailer M, Regidor PA. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Womens Health (Lond). 2021;17:17455065211020702.CrossRefPubMed Huber J, Mueller A, Sailer M, Regidor PA. Human papillomavirus persistence or clearance after infection in reproductive age. What is the status? Review of the literature and new data of a vaginal gel containing silicate dioxide, citric acid, and selenite. Womens Health (Lond). 2021;17:17455065211020702.CrossRefPubMed
7.
go back to reference Siqueira JD, Alves BM, Castelo Branco ABC, Duque KCD, Bustamante-Teixeira MT, Soares EA, Levi JE, Azevedo E, Silva G, Soares MA. Comparison of four different human papillomavirus genotyping methods in cervical samples: addressing method-specific advantages and limitations. Heliyon. 2024;10(3):e25474.CrossRefPubMedPubMedCentral Siqueira JD, Alves BM, Castelo Branco ABC, Duque KCD, Bustamante-Teixeira MT, Soares EA, Levi JE, Azevedo E, Silva G, Soares MA. Comparison of four different human papillomavirus genotyping methods in cervical samples: addressing method-specific advantages and limitations. Heliyon. 2024;10(3):e25474.CrossRefPubMedPubMedCentral
8.
go back to reference Desai KT, Adepiti CA, Schiffman M, et al. Redesign of a rapid, lowcost HPV typing assay to support risk-based cervical screening and management. Int J Cancer. 2022;151(7):1142–9.CrossRefPubMedPubMedCentral Desai KT, Adepiti CA, Schiffman M, et al. Redesign of a rapid, lowcost HPV typing assay to support risk-based cervical screening and management. Int J Cancer. 2022;151(7):1142–9.CrossRefPubMedPubMedCentral
9.
go back to reference Inturrisi F, de Sanjosé S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: a cross-sectional study. Int J Cancer. 2024;154(2):241–50.CrossRefPubMed Inturrisi F, de Sanjosé S, Desai KT, Dagnall C, Egemen D, Befano B, et al. A rapid HPV typing assay to support global cervical cancer screening and risk-based management: a cross-sectional study. Int J Cancer. 2024;154(2):241–50.CrossRefPubMed
10.
go back to reference Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, Jawadu S, de Sanjosé S, Schiffman M, Tang JH, Smith JS. Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi. Infect Agent Cancer. 2024;19(1):24.CrossRefPubMedPubMedCentral Mungo C, Guliam A, Chinula L, Inturrisi F, Msowoya L, Mkochi T, Jawadu S, de Sanjosé S, Schiffman M, Tang JH, Smith JS. Comparison of the ScreenFire and Xpert HPV assays for the detection of human papillomavirus and cervical precancer among women living with HIV in Malawi. Infect Agent Cancer. 2024;19(1):24.CrossRefPubMedPubMedCentral
11.
go back to reference Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, Zhang Y, Qu X, Wu R. AmpFire HPV and ScreenFire RS HPV Validation Trial. Am J Clin Pathol. 2024;161(6):535–42.CrossRefPubMed Hou J, Belinson JL, Du H, Li C, Zhang W, Zhang L, Zhang Y, Qu X, Wu R. AmpFire HPV and ScreenFire RS HPV Validation Trial. Am J Clin Pathol. 2024;161(6):535–42.CrossRefPubMed
12.
go back to reference Musa J, Kim K, Zheng Y, Qu Y, Joyce BT, Wang J, et al. Accelerated epigenetic age among women with invasive cervical Cancer and HIV-Infection in Nigeria. Front Public Health. 2022;10:834800.CrossRefPubMedPubMedCentral Musa J, Kim K, Zheng Y, Qu Y, Joyce BT, Wang J, et al. Accelerated epigenetic age among women with invasive cervical Cancer and HIV-Infection in Nigeria. Front Public Health. 2022;10:834800.CrossRefPubMedPubMedCentral
Metadata
Title
Analytic performance of ScreenFire HPV RS assay Zebra BioDome format and its potential for large-scale population HPV screening
Authors
Jun Wang
Godwin Imade
Alani S. Akanmu
Jonah Musa
Rose Anorlu
Yinan Zheng
Olga Garcia-Bedoya
Gloria I. Sanchez
Jerome Belinson
Kyeezu Kim
Mamoudou Maiga
Demirkan B. Gursel
Atiene S. Sagay
Folasade T. Ogunsola
Robert L. Murphy
Lifang Hou
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Infectious Agents and Cancer / Issue 1/2024
Electronic ISSN: 1750-9378
DOI
https://doi.org/10.1186/s13027-024-00622-2
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now